

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
Date of first issue: 21.05.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Mometasone Cream Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.
30 Hudson Street, 33rd floor
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number

+1-215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Long-term (chronic) aquatic hazard, Category 2	H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Warning

Hazard statements : H315 Causes skin irritation.
H319 Causes serious eye irritation.
H361d Suspected of damaging the unborn child.

SAFETY DATA SHEET



Mometasone Cream Formulation



Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
Date of first issue: 21.05.2017

H411 Toxic to aquatic life with long lasting effects.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:

2-Methyl-2,4-pentanediol

Additional Labelling

EUH212 Warning! Hazardous respirable dust may be formed when used. Do not breathe dust.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
2-Methyl-2,4-pentanediol	107-41-5 203-489-0 603-053-00-3	Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 2; H361d	>= 10 - < 20
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 100	>= 0,1 - < 0,25

For explanation of abbreviations see section 16.

Mometasone Cream Formulation

Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
Date of first issue: 21.05.2017

SECTION 4: First aid measures**4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes skin irritation.
Causes serious eye irritation.
Suspected of damaging the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
-

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire- : Vapours may form explosive mixtures with air.
-

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

fighting Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling : Do not get on skin or clothing.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

Do not breathe vapours.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
2-Methyl-2,4-pentanediol	107-41-5	OEL-RL (vapour fraction)	50 ppm	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			
		OEL- RL STEL/C (vapour fraction)	100 ppm	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			
		OEL- RL STEL/C (inhalable fraction, aerosol only)	20 mg/m3	ZA OEL

Mometasone Cream Formulation

Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
Date of first issue: 21.05.2017

	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents			
Titanium dioxide	13463-67-7	OEL-RL	10 mg/m ³	ZA OEL
	Further information: Occupational Exposure Limits - Restricted Limits For Hazardous Chemical Agents, denotes carcinogenicity, which is based on GHS categorisation, including category 1A, 1B			
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal

This substance(s) is not bioavailable and therefore does not contribute to a dust inhalation hazard.

Titanium dioxide

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
2-Methyl-2,4-pentanediol	Workers	Inhalation	Long-term systemic effects	44,43 mg/m ³
	Workers	Inhalation	Long-term local effects	49 mg/m ³
	Workers	Inhalation	Acute local effects	98 mg/m ³
	Workers	Skin contact	Long-term systemic effects	63 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	7,83 mg/m ³
	Consumers	Inhalation	Long-term local effects	25 mg/m ³
	Consumers	Inhalation	Acute local effects	49 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	22,5 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	2,25 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
2-Methyl-2,4-pentanediol	Fresh water	0,429 mg/l
	Freshwater - intermittent	4,29 mg/l
	Marine water	0,0429 mg/l
	Sewage treatment plant	20 mg/l
	Fresh water sediment	1,59 mg/kg dry weight (d.w.)
	Marine sediment	0,159 mg/kg dry weight (d.w.)
	Soil	0,066 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

Appearance	:	cream
Colour	:	white to off-white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	> 93,3 °C
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	Not classified as a flammability hazard
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids)	:	Not applicable
Particle size	:	No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	Vapours may form explosive mixture with air. Can react with strong oxidizing agents.
---------------------	---	---

10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**2-Methyl-2,4-pentanediol:**

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 420
Acute dermal toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity

Mometasone:

Acute oral toxicity	:	LD50 (Rat): > 2.000 mg/kg LD50 (Mouse): > 2.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3,3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose. LC50 (Mouse): > 3,2 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute toxicity (other routes of administration)	:	LD50 (Rat): 300 mg/kg Application Route: Subcutaneous Symptoms: Breathing difficulties

Skin corrosion/irritation

Causes skin irritation.

Components:**2-Methyl-2,4-pentanediol:**

Result	:	Skin irritation
Remarks	:	Based on national or regional regulation.

Mometasone:

Species	:	Rabbit
Result	:	No skin irritation

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**2-Methyl-2,4-pentanediol:**

Result	:	Irritation to eyes, reversing within 21 days
Remarks	:	Based on national or regional regulation.

Mometasone:

Species	:	Rabbit
Result	:	No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**2-Methyl-2,4-pentanediol:**

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative

Mometasone:

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Assessment	:	Does not cause skin sensitisation.
Result	:	negative
Remarks	:	The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Germ cell mutagenicity

Not classified based on available information.

Components:**2-Methyl-2,4-pentanediol:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
		Test Type: In vitro mammalian cell gene mutation test
		Method: OECD Test Guideline 476
		Result: negative
		Test Type: Chromosome aberration test in vitro
		Result: negative

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

||

Mometasone:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster lung cells Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: positive
		Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity- Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Mometasone:**

Species	:	Rat
Application Route	:	Inhalation
Exposure time	:	2 Years
Dose	:	0.067 mg/kg body weight
Result	:	negative

Species	:	Mouse
Application Route	:	Inhalation
Exposure time	:	19 Months
Dose	:	0.160 mg/kg body weight
Result	:	negative

Mometasone Cream Formulation

Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
Date of first issue: 21.05.2017

Reproductive toxicity

Suspected of damaging the unborn child.

Components:**2-Methyl-2,4-pentanediol:**

- | | | |
|------------------------------------|---|--|
| Effects on fertility | : | Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 443
Result: negative |
| Effects on foetal development | : | Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 443
Result: positive |
| Reproductive toxicity - Assessment | : | Some evidence of adverse effects on development, based on animal experiments. |

Mometasone:

- | | | |
|-------------------------------|---|---|
| Effects on fertility | : | Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0,015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced foetal weight
Result: No effects on fertility, Effect on reproduction capacity |
| Effects on foetal development | : | Test Type: Embryo-foetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0,06 mg/kg body weight
Result: Embryotoxic effects., Teratogenicity and developmental toxicity |
| | | Test Type: Embryo-foetal development
Species: Rat
Application Route: Dermal
Embryo-foetal toxicity: LOAEL: 0,3 mg/kg body weight
Result: Embryo-foetal toxicity |
| | | Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Dermal
Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed. |
| | | Test Type: Embryo-foetal development
Species: Rat
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight
Result: Effects on newborn |

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

	Test Type: Embryo-foetal development
	Species: Rabbit
	Application Route: Oral
	Embryo-foetal toxicity: LOAEL: 0,7 mg/kg body weight
	Result: Embryo-foetal toxicity, Malformations were observed.
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks	: Based on available data, the classification criteria are not met.
---------	---

STOT - repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Exposure routes	: inhalation (dust/mist/fume)
Target Organs	: Immune system, Liver, Kidney, Skin
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****2-Methyl-2,4-pentanediol:**

Species	: Rat
NOAEL	: >= 450 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks
Method	: OECD Test Guideline 408

Mometasone:

Species	: Rat
NOAEL	: 0,005 mg/kg
LOAEL	: 0,3 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Dog
NOAEL	: 0,5 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Mometasone Cream Formulation

Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
Date of first issue: 21.05.2017

Species : Rat
NOAEL : 0,00013 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog
NOAEL : 0,0005 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

|| Not applicable

Experience with human exposure**Components:****2-Methyl-2,4-pentanediol:**

|| Eye contact : Target Organs: Eyes
Symptoms: Irritation

Mometasone:

|| Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

|| Skin contact : Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

|| Remarks : Dermal absorption possible

SECTION 12: Ecological information**12.1 Toxicity****Components:****2-Methyl-2,4-pentanediol:**

|| Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8.510 mg/l
Exposure time: 96 h

Mometasone Cream Formulation

Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
 Date of first issue: 21.05.2017

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Ceriodaphnia dubia (water flea)): 2.800 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	EC10 (Raphidocelis subcapitata (freshwater green alga)): > 429 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	: NOEC (Bacteria): 200 mg/l Exposure time: 10 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 25 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Mometasone:

Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): 0,11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility
	LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
	EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	: EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
	NOEC : 1.000 mg/l Exposure time: 3 h

Mometasone Cream Formulation

Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
Date of first issue: 21.05.2017

	Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC: 0,00014 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 0,34 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic toxicity)	: 100

12.2 Persistence and degradability

Components:**2-Methyl-2,4-pentanediol:**

Biodegradability	: Result: Readily biodegradable. Biodegradation: 81 % Exposure time: 28 d Method: OECD Test Guideline 301F
------------------	---

Mometasone:

Biodegradability	: Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	: Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:**2-Methyl-2,4-pentanediol:**

Partition coefficient: n-octanol/water	: log Pow: < 4 Remarks: Calculation
--	--

Mometasone:

Bioaccumulation	: Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 107,1 Method: OECD Test Guideline 305
Partition coefficient: n-octanol/water	: log Pow: 4,68

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

12.4 Mobility in soil**Components:****Mometasone:**

|| Distribution among environmental compartments : log Koc: 4,02

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information**14.1 UN number**

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

Mometasone Cream Formulation

Version 5.0 Revision Date: 06.04.2024 SDS Number: 1688408-00018 Date of last issue: 30.09.2023
 Date of first issue: 21.05.2017

(Mometasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Mometasone)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Mometasone)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Mometasone)

IATA : Environmentally hazardous substance, solid, n.o.s.
(Mometasone)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	: 9	
ADR	: 9	
RID	: 9	
IMDG	: 9	
IATA	: 9	

14.4 Packing group

ADN
 Packing group : III
 Classification Code : M7
 Hazard Identification Number : 90
 Labels : 9

ADR
 Packing group : III
 Classification Code : M7
 Hazard Identification Number : 90
 Labels : 9
 Tunnel restriction code : (-)

RID
 Packing group : III
 Classification Code : M7
 Hazard Identification Number : 90
 Labels : 9

IMDG
 Packing group : III
 Labels : 9
 EmS Code : F-A, S-F

IATA (Cargo)
 Packing instruction (cargo aircraft) : 956
 Packing instruction (LQ) : Y956
 Packing group : III
 Labels : Miscellaneous

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

IATA (Passenger)

Packing instruction (passenger aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

14.5 Environmental hazards**ADN**

Environmentally hazardous	:	yes
---------------------------	---	-----

ADR

Environmentally hazardous	:	yes
---------------------------	---	-----

RID

Environmentally hazardous	:	yes
---------------------------	---	-----

IMDG

Marine pollutant	:	yes
------------------	---	-----

IATA (Passenger)

Environmentally hazardous	:	yes
---------------------------	---	-----

IATA (Cargo)

Environmentally hazardous	:	yes
---------------------------	---	-----

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks	:	Not applicable for product as supplied.
---------	---	---

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS	:	not determined
------	---	----------------

DSL	:	not determined
-----	---	----------------

IECSC	:	not determined
-------	---	----------------

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

Full text of H-Statements

H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
H360Df : May damage the unborn child. Suspected of damaging fertility.
H361d : Suspected of damaging the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure if inhaled.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
Skin Irrit. : Skin irritation
STOT RE : Specific target organ toxicity - repeated exposure
ZA OEL : South Africa. The Regulations for Hazardous Chemical Agents, Occupational Exposure Limits
ZA OEL / OEL-RL : Occupational Exposure Limit Restricted limit - 8- hour exposure or equivalent (12 hour shifts)
ZA OEL / OEL- RL STEL/C : Occupational Exposure Limit Restricted limit - Short term occupational exposure limits / ceiling limits

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN

Mometasone Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.0	06.04.2024	1688408-00018	Date of first issue: 21.05.2017

- United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Irrit. 2	H315
Eye Irrit. 2	H319
Repr. 2	H361d
Aquatic Chronic 2	H411

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN